Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Salofalk 3g gastro-resistant modified-release gran sachets
0105010B0BDAKAZ
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 12,391 |
|
Salofalk 1.5g gastro-resistant modified-release gran sachets
0105010B0BDAHAU
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 7,423 |
|
Salofalk 1g suppositories
0105010B0BDAIAJ
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 6,300 |
|
Salofalk 2g/59ml enema
0105010B0BDADAL
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 3,917 |
|
Salofalk 1g gastro-resistant modified-release gran sachets
0105010B0BDAFAX
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 3,770 |
|
Salofalk 1g/application foam enema
0105010B0BDAEAK
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 2,842 |
|
Salofalk 500mg gastro-resistant tablets
0105010B0BDAJAW
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 2,294 |
|
Salofalk 500mg suppositories
0105010B0BDACAB
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 1,702 |
|
Salofalk 500mg gast res MR gran sachets
0105010B0BDAGAP
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 1,592 |
|
Salofalk 1g gastro-resistant tablets
0105010B0BDALBC
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 1,172 |
|
Salofalk 250mg gastro-resistant tablets
0105010B0BDAAAH
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 425 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.